Institutional shares held 24.4 Million
483K calls
364K puts
Total value of holdings $4.24B
$83.8M calls
$63M puts
Market Cap $4.2B
25,664,300 Shares Out.
Institutional ownership 95.27%
# of Institutions 311


Latest Institutional Activity in KRYS

Top Purchases

Q3 2024
Avoro Capital Advisors LLC Shares Held: 2.62M ($429M)
Q3 2024
Segall Bryant & Hamill, LLC Shares Held: 157K ($25.7M)
Q3 2024
State Street Corp Shares Held: 1.45M ($238M)
Q3 2024
Soleus Capital Management, L.P. Shares Held: 217K ($35.5M)
Q3 2024
Invesco Ltd. Shares Held: 366K ($59.8M)

Top Sells

Q3 2024
Redmile Group, LLC Shares Held: 810K ($133M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 438K ($71.7M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 301K ($49.3M)
Q3 2024
Woodline Partners LP Shares Held: 180K ($29.4M)
Q3 2024
Jennison Associates LLC Shares Held: 410K ($67.1M)

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.


Insider Transactions at KRYS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
90K Shares
From 4 Insiders
Exercise of conversion of derivative security 90K shares
Sell / Disposition
477K Shares
From 8 Insiders
Payment of exercise price or tax liability 28.5K shares
Open market or private sale 443K shares
Bona fide gift 5K shares

Track Institutional and Insider Activities on KRYS

Follow Krystal Biotech, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KRYS shares.

Notify only if

Insider Trading

Get notified when an Krystal Biotech, Inc. insider buys or sells KRYS shares.

Notify only if

News

Receive news related to Krystal Biotech, Inc.

Track Activities on KRYS